Rocked by allegations, Novena Global Healthcare board takes over running of firm from Loh cousins
Sinopharm Capital among investors guarding their interests over the company's accounts
Add BT as a preferred source
Anita Gabriel
Singapore
A GROUP of chafed investors in Novena Global Healthcare Group (NGHG) is moving to guard its interests on concerns about the company's accounts. Among these investors: Sinopharm Capital, the private equity arm of Chinese pharmaceutical giant Sinopharm.
On Friday, NGHG's board shot out a statement that it was "deeply concerned" by recent developments, and has set up a special committee to investigate allegations that the audit signatures on the firm's accounts were forged and to "restructure and scrutinise" its affairs.
TRENDING NOW
Lamborghini-driving boss of Eminent Frog Porridge charged with S$3.8 million tax evasion, money laundering
Not in education, employment or training: Why more Hong Kong youths are opting out of work
With AI, it’s not about coding better; workers need to think better: Koh Boon Hwee
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
